30 EMPIRE randomized 116 ST-segment elevation myocardial infarction patients to exenatide or placebo in parallel groups and showed that at 6 months (n=58), exenatide reduced E/e with improved strain parameters, measured by conventional and speckle tracking echocardiography (NCT01580514)
Ready to discuss your weight loss options
Onset and offset of therapeutic effects are directly related to the drug's half-life
Injectable forms were made and worked a little bit, but not satisfactorily
At least three other states California, New Hampshire and North Carolina have recently limited or plan to throttle access to GLP-1s for weight-loss, according to health policy think tank KFF
Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM